Literature DB >> 23836235

Global control of hepatitis C: where challenge meets opportunity.

David L Thomas1.   

Abstract

We are entering an important new chapter in the story of hepatitis C virus (HCV) infection. There are clear challenges and opportunities. On the one hand, new HCV infections are still occurring, and an estimated 185 million people are or have previously been infected worldwide. Most HCV-infected persons are unaware of their status yet are at risk for life-threatening diseases such as cirrhosis and hepatocellular carcinoma (HCC), whose incidences are predicted to rise in the coming decade. On the other hand, new HCV infections can be prevented, and those that have already occurred can be detected and treated--viral eradication is even possible. How the story ends will largely be determined by the extent to which these rapidly advancing opportunities overcome the growing challenges and by the vigor of the public health response.

Entities:  

Mesh:

Year:  2013        PMID: 23836235      PMCID: PMC4937625          DOI: 10.1038/nm.3184

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  97 in total

1.  Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.

Authors:  Eileen Foy; Kui Li; Rhea Sumpter; Yueh-Ming Loo; Cynthia L Johnson; Chunfu Wang; Penny Mar Fish; Mitsutoshi Yoneyama; Takashi Fujita; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

2.  Direct economic burden of chronic hepatitis C virus in a United States managed care population.

Authors:  Keith L Davis; Debanjali Mitra; Jasmina Medjedovic; Cynthia Beam; Vinod Rustgi
Journal:  J Clin Gastroenterol       Date:  2011-02       Impact factor: 3.062

Review 3.  Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis.

Authors:  Sushmita Shivkumar; Rosanna Peeling; Yalda Jafari; Lawrence Joseph; Nitika Pant Pai
Journal:  Ann Intern Med       Date:  2012-10-16       Impact factor: 25.391

4.  Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies.

Authors:  Priti R Patel; A Kirsten Larson; Amanda D Castel; Lilia M Ganova-Raeva; Robert A Myers; Brenda J Roup; Katherine P Farrell; Leslie Edwards; Omana Nainan; John P Krick; David Blythe; Anthony E Fiore; Jeffrey C Roche
Journal:  JAMA       Date:  2006-10-25       Impact factor: 56.272

5.  Costs of hepatitis C.

Authors:  J P Leigh; C L Bowlus; B N Leistikow; M Schenker
Journal:  Arch Intern Med       Date:  2001-10-08

6.  The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection.

Authors:  S Barrett; J Goh; B Coughlan; E Ryan; S Stewart; A Cockram; J C O'Keane; J Crowe
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

Review 7.  Natural history of hepatitis C.

Authors:  David L Thomas; Leonard B Seeff
Journal:  Clin Liver Dis       Date:  2005-08       Impact factor: 6.126

8.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Exploratory study of oral combination antiviral therapy for hepatitis C.

Authors:  Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

View more
  128 in total

1.  Viral hepatitis: A new HCV cell culture model for the next clinical challenges.

Authors:  Che C Colpitts; Thomas F Baumert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-06       Impact factor: 46.802

2.  Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics.

Authors:  Jinjin Zhang; Jered C Garrison; Larisa Y Poluektova; Tatiana K Bronich; Natalia A Osna
Journal:  Biomaterials       Date:  2015-08-08       Impact factor: 12.479

3.  Outflanking HCV.

Authors:  Zhigang Tian
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

4.  Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2013-12-21       Impact factor: 7.527

5.  Viral hepatitis: Treating hepatitis C in injection drug users.

Authors:  Vincent Soriano; Lucía Gallego
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-03       Impact factor: 46.802

6.  Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site.

Authors:  Kejia Ding; Annie Wang; Mark A Boerneke; Sergey M Dibrov; Thomas Hermann
Journal:  Bioorg Med Chem Lett       Date:  2014-05-14       Impact factor: 2.823

7.  Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.

Authors:  Long Zhang; David D Celentano; Nguyen Le Minh; Carl A Latkin; Shruti H Mehta; Constantine Frangakis; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Vu Minh Quan; Vivian F Go
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

8.  Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.

Authors:  Koji Takayama; Norihiro Furusyo; Eiichi Ogawa; Hiroaki Ikezaki; Motohiro Shimizu; Masayuki Murata; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015

Review 10.  Hepatitis C virus infection: Are there still specific problems with genotype 3?

Authors:  Claire Gondeau; Georges Philippe Pageaux; Dominique Larrey
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.